“
TL;DR
The authors propose integrating publicly available molecular data to identify pharmacoepigenetic interactions for more precise personalized medicine.
Cambridge Prisms: Precision Medicine · 6 authors, 10 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The authors propose integrating publicly available molecular data to identify pharmacoepigenetic interactions for more precise personalized medicine.
This narrative review explores the field of pharmacoepigenetics, which examines how epigenetic modifications, such as DNA methylation, influence drug response. The authors synthesize evidence from human studies indicating that epigenetic variation in drug-metabolizing genes (e.g., CYP3A4, CYP2D6, ABCB1) can impact pharmacokinetics and clinical outcomes for drugs like antipsychotics, warfarin, and aspirin. They highlight that genetic variation explains only 10–30% of drug response differences, suggesting epigenetics contributes to the remainder. A key proposal is to use large, publicly available databases (e.g., GoDMC, GTEx, EWAS Catalog) to systematically identify pharmacoepigenetic interactions, illustrated with a clozapine case study. The review concludes that integrating multi-omics data could advance our understanding of biological mechanisms to support the development of more personalized therapeutic interventions.